Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EBT: 2018-2024

Historic EBT for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to -$44.5 million.

  • Silence Therapeutics' EBT rose 40.96% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.2 million, marking a year-over-year increase of 18.84%. This contributed to the annual value of -$44.5 million for FY2024, which is 16.53% up from last year.
  • Per Silence Therapeutics' latest filing, its EBT stood at -$44.5 million for FY2024, which was up 16.53% from -$53.3 million recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' EBT ranged from a high of -$44.5 million in FY2024 and a low of -$63.1 million during FY2021.
  • For the 3-year period, Silence Therapeutics' EBT averaged around -$52.1 million, with its median value being -$53.3 million (2023).
  • As far as peak fluctuations go, Silence Therapeutics' EBT tumbled by 58.49% in 2020, and later rose by 16.53% in 2024.
  • Silence Therapeutics' EBT (MRY) stood at -$46.3 million in 2020, then plummeted by 36.32% to -$63.1 million in 2021, then grew by 7.08% to -$58.6 million in 2022, then increased by 9.13% to -$53.3 million in 2023, then rose by 16.53% to -$44.5 million in 2024.
  • Its EBT stands at -$44.5 million for FY2024, versus -$53.3 million for FY2023 and -$58.6 million for FY2022.